VISCHER advises Basel-Stadt on the implementation of the ESC
VISCHER provided comprehensive legal advice to the Canton of Basel-Stadt on the implementation of the Eurovision Song Contest 2025.
VISCHER advises Basel-Stadt on hosting the UEFA Women’s EURO 2025
VISCHER provided comprehensive legal advice and support to Basel-Stadt in hosting the UEFA Women's EURO 2025.
VISCHER advises Primeo Energie, Groupe E and ewb on the sale of MOVE
Primeo Energie, Groupe E and ewb sell MOVE Mobility.
Nuclidium AG closes Series B financing round
NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, announced the successful closing of its Series B financing round, raising CHF 79m (EUR 84m).
VISCHER advises synaforce on the acquisition of ServerBase
The synaforce Group acquires ServerBase AG, an established Swiss cloud platform based in Bachenbülach in the Canton of Zurich. VISCHER acted as legal counsel to the synaforce Group on this transaction.
VISCHER advised Picanol in its acquisition of Osterwalder
Tessenderlo Group, through its group company Picanol NV, has acquired the activities of Osterwalder AG, a Swiss manufacturer of electric powder presses.
Snyk acquires Invariant Labs AG
Snyk Ltd., the leader in secure AI software development, acquires Invariant Labs AG, an AI security research company and spin-off of ETH Zurich based in Zurich.
Easternmed Real Estate Capital PLC acquires a luxury hotel residence
VISCHER advised Easternmed Real Estate Capital PLC in its acquisition of a new prime commercial property (hotel residence) in one of the most illustrious streets in Geneva.
Swissroc Group acquires a new industrial building in Geneva
Swissroc Industrial Opportunities (CH) SA has acquired a 4,200 m² light industrial building in the commune of Thônex (Geneva) from a professional investor. Built in 1991, this asset is strategically located in the heart of a dynamic industrial zone, in the immediate vicinity of the Geneva region's major communication routes.
Mosanna Therapeutics raises USD 80m in Series-A-Funding
Mosanna Therapeutics AG closed its USD 80m Series A funding round.